Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epidemiological studies on human papillomavirus (HPV)
ISRCTN90378590Phase 3Completed
- Sponsor
- London School of Hygiene & Tropical Medicine
- Start
- Oct 2008
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised trial of human papillomavirus type 16 L1 capsid protein antigen in human papillomavirus infection, sponsored by London School of Hygiene & Tropical Medicine. Primary endpoints: Prevalence at enrolment and incidence of genital HPV infection at Month 12, Prevalence of cervical pathology at enrolment and 1 more. Started Oct 2008; status: completed.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigen
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on ISRCTN90378590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN90378590.